Stada CEO Says IPO Planned This Year in Boost to European Market
Pills in the hand of a worker in the quality control laboratory at the Stada Arzneimittel AG factory in Bad Vilbel, Germany.
Photographer: Alex Kraus/BloombergStada Arzneimittel AG is in a better position for an initial public offering this fall, the German drugmaker’s chief executive said, boosting prospects for Europe’s market after delaying plans earlier this year.
“A larger pipeline of in-licensed drugs and our European footprint bode well for Stada,” CEO Peter Goldschmidt said in an interview this week. The company secured a record number of 50 new in-licensing deals in the first half of this year, he added.